Newark, NJ, May 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Sanjeev Luther, President and Chief Executive Officer, was named the 2019 Corporate Honoree by the American Cancer Society (ACS). This prestigious honor will be given to Mr. Luther on May 18th at the 12th Annual Starry Night Gala.
Mr. Luther’s passion for driving cancer research can be reflected in the success he has made at Rafael Pharmaceuticals. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attacks hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Under Mr. Luther’s leadership, Rafael has made significant progress in its clinical development, including two Phase 3 programs of its lead molecule CPI-613® (devimistat) for patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML) and several orphan designations. Mr. Luther also brings thirty years of experience to Rafael from leading Fortune 500 pharmaceutical companies.
“I would like to thank the ACS for this truly humbling honor,” said Mr. Luther. “It is because of the researchers, leaders, volunteers and staff at the ACS that there is hope for patients, survivors and families. Together, with ACS and the passionate team at Rafael, I believe that we will continue to positively impact lives and make advancements for future generations as we live by Rafael's motto, ‘To Save A Life Is To Save A Universe.’”
The Starry Night Gala is held each year to celebrate the accomplishments of the ACS and to look forward to future successes by raising money for more research, treatment options, and survivors. It is attended by healthcare professionals, top business leaders and philanthropic individuals. Honorees, or “Inspirers of Hope,” are recognized each year for their dedication to cancer research, cancer treatment and cancer recovery. Mr. Luther will be one of four honorees recognized at this year’s event.
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is clinical stage company and a leader in the growing field of cancer metabolism-based therapeutics. Rafael’s primary objective is to develop and commercialize innovative, highly selective, well tolerated and highly effective anti-cancer agents by selectively targeting the altered metabolism in cancer cells. Rafael’s first-in-class clinical lead compound, CPI-613®(devimistat), is being evaluated in multiple ongoing/completed Phase I, II, and III clinical studies. CPI-613®(devimistat) has been granted orphan drug designation for the treatment of Pancreatic Cancer, Acute Myeloid Leukemia (AML), Peripheral T-Cell Lymphoma (PTCL), Burkitt Lymphoma and Myelodysplastic Syndromes (MDS). Rafael Pharmaceuticals is an affiliate of Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more information, visit http://www.rafaelpharma.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise.
In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.